Group A Streptococcus epidemiology and vaccine implications

Clinical Infectious Diseases

Volumn 45, Issue 7, 2007, Pages 863-865

  Cohen Poradosu, Ronit ^a   Kasper, Dennis L ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE VACCINE; M PROTEIN; PNEUMOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; BACTERIAL ANTIGEN; CARRIER PROTEIN; OUTER MEMBRANE PROTEIN; STREPTOCOCCAL M PROTEIN; UNCLASSIFIED DRUG;

HUMAN; IMMUNE RESPONSE; NECROTIZING FASCIITIS; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SEROTYPE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME; UNITED STATES; VACCINATION; HEALTH; IMMUNOLOGY; PATHOGENICITY; STREPTOCOCCUS PYOGENES;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; UNITED STATES; WORLD HEALTH;

EID: 34848837631     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521263     Document Type: Note

References (36)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685-94.
2. O'Brien KL, Beall B, Barrett NL, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002; 35:268-76.
3. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). J Clin Microbiol 2005; 43:1678-83.
4. Lamagni TL, Efstratiou A, Vuopio-Varkila J, Jasir A, Schalen C. The epidemiology of severe Streptococcus pyogenes associated disease in Europe. Euro Surveill 2005; 10:179-84.
5. Shulman ST, Stollerman G, Beall B, Dale JB, Tanz RR. Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States. Clin Infect Dis 2006; 42:441-7.
6. Martin JM, Barbadora KA. Continued high caseload of rheumatic fever in western Pennsylvania: possible rheumatogenic emm types of Streptococcus pyogenes. J Pediatr 2006; 149:58-63.
7. Wald ER, Dashefsky B, Feidt C, Chiponis D, Byers C. Acute rheumatic fever in western Pennsylvania and the tristate area. Pediatrics 1987; 80:371-4.
8. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987; 316:421-7.
9. Lee GM, Wessels MR. Changing epidemiology of acute rheumatic fever in the United States. Clin Infect Dis 2006; 42:448-50.
10. Leads from the MMWR: acute rheumatic fever at a Navy training center - San Diego, California. JAMA 1988; 259:1782, 1787.
11. Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002; 35:950-9.
12. Collis WRF. Intravenous vaccines of hemolytic streptococci in rheumatism in childhood. Lancet 1932; 220:1261-4.
13. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol 1962; 89:307-13.
14. Polly SM, Waldman RH, High P, Wittner MK, Dorfman A. Protective studies with a group A streptococcal M protein vaccine. II. Challenge of volunteers after local immunization in the upper respiratory tract. J Infect Dis 1975; 131:217-24.
15. Beachey EH, Stollerman GH, Johnson RH, Ofek I, Bisno AL. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med 1979; 150:862-77.
16. Bronze MS, Courtney HS, Dale JB. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. J Immunol 1992; 148:888-93.
17. Bronze MS, Beachey EH, Seyer JM, Dale JB. Protective and heart-cross-reactive epitopes of type 19 streptococcal M protein. Trans Assoc Am Physicians 1987; 100:80-4.
18. Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination: report of three cases. JAMA 1969; 207:1115-9.
19. Kotloff KL, Corretti M, Palmer K, et al. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004; 292:709-15.
20. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41:1114-22.
21. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70:2171-7.
22. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007; 45:853-62 (in this issue).
23. Ikebe T, Hirasawa K, Suzuki R, et al. Distribution of emm genotypes among group A streptococcus isolates from patients with severe invasive streptococcal infections in Japan, 2001-2005. Epidemiol Infect 2007;9 Feb:1-3.
24. Abdissa A, Asrat D, Kronvall G, et al. High diversity of group A streptococcal emm types among healthy schoolchildren in Ethiopia. Clin Infect Dis 2006; 42:1362-7.
25. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995; 171:93-8.
26. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348:271-2.
27. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784-92.
28. Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles - report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 2005; 41:1150-6.
29. Cleary PP, Matsuka YV, Huynh T, Lam H, Olmsted SB. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 2004; 22:4332-41.
30. Ji Y, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization ofmice by the group A streptococcus. Infect Immun 1997; 65:2080-7.
31. Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005; 73:7878-86.
32. Kawabata S, Kunitomo E, Terao Y, et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001; 69:924-30.
33. Guzman CA, Talay SR, Molinari G, Medina E, Chhatwal GS. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999; 179:901-6.
34. Sabharwal H, Michon F, Nelson D, et al. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 2006; 193:129-35.
35. Vohra H, Dey N, Gupta S, et al. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 2005; 156:575-82.
36. Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187:1598-608.